Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD

• ONS-5010 is a recombinant mAb targeting VEGF, intended for wet AMD treatment, pending FDA approval.
• The FDA previously rejected the BLA due to CMC issues and lack of substantial evidence.

https://www.ophthalmologytimes.com/view/outlook-therapeutics-resubmits-bla-for-ons-5010-for-treatment-of-wet-amd